Premium
The anti‐interleukin‐1 in type 1 diabetes action trial—background and rationale
Author(s) -
Pickersgill Linda M.S.,
MandrupPoulsen Thomas R.
Publication year - 2009
Publication title -
diabetes/metabolism research and reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.307
H-Index - 110
eISSN - 1520-7560
pISSN - 1520-7552
DOI - 10.1002/dmrr.960
Subject(s) - medicine , diabetes mellitus , type 1 diabetes , type 2 diabetes , interleukin , beta cell , immunology , clinical trial , islet , proinflammatory cytokine , effector , pancreatic islets , apoptosis , inflammation , cytokine , endocrinology , biology , biochemistry
Type 1 diabetes (T1D) is caused by an inflammatory destruction of pancreatic beta‐cells. Pro‐inflammatory cytokines, in particular interleukin‐1 (IL‐1), have been suggested to be effector molecules based on the observations that pro‐inflammatory cytokines cause beta‐cell apoptosis in vitro and aggravate diabetes in vivo , and that inhibition of the action of these cytokines reduce diabetes incidence in animal models of type 1 diabetes and islet graft destruction. This review presents the rationale for and design of a recently launched double‐blind, multicenter, randomized clinical trial that investigates the effect of interleukin‐1 antagonism on beta‐cell function in subjects with T1D of recent‐onset. Copyright © 2009 John Wiley & Sons, Ltd.